For breast cancer, the most common therapeutic targets are CEA, CD70, ROR1, HER2, MUC1, EGFR, CD133, MSLN, EpCAM, disialoganglioside (GD2), and the hepatocyte growth factor receptor (HGFR) (153, 154). This evidence concerns the gene MET and breast carcinoma.